Recent advances in the discovery of small-molecule inhibitors for inflammatory bowel disease therapy
European Journal of Medicinal Chemistry · 2026-11 · 317 · 119080
DOI: 10.1016/j.ejmech.2026.119080 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Medicinal Chemistry, 2026-11. Verfasst von Huiheng Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Shenzhen Technology University, Shenzhen, Guangdong, 518118, China. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Small Molecule Libraries, Drug Discovery, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit nennt 159 Literaturangaben. Gefördert von: Shenzhen Technology University, Shenzhen Science and Technology Innovation Program, Shenzhen Science and Technology Innovation Commission.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a chronic condition characterized by recurrent intestinal ulceration. The rising global incidence of IBD in recent years has increased disease burden and highlighted the urgent need for more effective and safer treatments. Small-molecule therapeutics targeting critical pathogenic pathways represent a rapidly advancing area of IBD drug development, offering the advantages of stronger target binding affinity, better specificity, and more favorable pharmacokinetic performance compared to conventional therapies. This review summarizes the progress made in IBD small-molecule drugs in the past 5 years, covering the association between related targets and IBD pathogenesis, a series of new compounds acting on distinct molecular targets, including those that have advanced recently to clinical trials as well as those demonstrating promising anti-IBD activity in preclinical studies. The targets include key proteins (BRD4, PDE4, NLRP3), kinases (JAK, RIPK, SIK, IRAK), and G protein-coupled receptors (CCR6, CXCR4). For preclinical compounds, we highlighted the key structural modification process and structure-activity relationship (SAR) studies, summarizing their anti-inflammatory and intestinal protective activities demonstrated in both in vitro and in vivo experiments. Overall, this review aims to facilitate the rational development of next-generation, more effective, and safer small-molecule therapeutics for IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Shenzhen Technology University, Shenzhen, Guangdong, 518118, China.
- College of Pharmacy, Shenzhen Technology University, Shenzhen, Guangdong, 518118, China. Electronic address: huangyujie@sztu.edu.cn.
- College of Pharmacy, Shenzhen Technology University, Shenzhen, Guangdong, 518118, China. Electronic address: wangsiyuan@sztu.edu.cn.
Förderung
- Shenzhen Technology University
- Shenzhen Science and Technology Innovation Program
- Shenzhen Science and Technology Innovation Commission
Zitieren
APA
Lin, H., Wen, S., Huang, Y., & Wang, S. (2026). Recent advances in the discovery of small-molecule inhibitors for inflammatory bowel disease therapy. European Journal of Medicinal Chemistry, 317, 119080. https://doi.org/10.1016/j.ejmech.2026.119080
Vancouver
Lin H, Wen S, Huang Y, Wang S. Recent advances in the discovery of small-molecule inhibitors for inflammatory bowel disease therapy. European Journal of Medicinal Chemistry. 2026;317:119080. doi:10.1016/j.ejmech.2026.119080
BibTeX
@article{Lin2026,
author = {Lin, Huiheng and Wen, Shun and Huang, Yujie and Wang, Siyuan},
title = {Recent advances in the discovery of small-molecule inhibitors for inflammatory bowel disease therapy},
journal = {European Journal of Medicinal Chemistry},
year = {2026},
volume = {317},
pages = {119080},
doi = {10.1016/j.ejmech.2026.119080}
}
EUVIMED